Barclays
SVNT

Barclays’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

Barclays’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,800
Closed -$7K – 7879
2013
Q2 		$7K Buy
+12,800
New +$8.92K ﹤0.01% 7284

Other funds holding SVNT

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FHC
First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return
PSC
Prentiss Smith & Co Brattleboro, Vermont $172M AUM 21.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Barclays's SVNT Position: Q4 2013 in Review

Barclays sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q4 2013, closing a stake of 10,944 shares.

Barclays first reported a position in SVNT in Q2 2013 and held it in 2 quarters. The position peaked at $110K in Q2 2013. 7 funds tracked by Wall St. Rank hold SVNT as of Q4 2013.

  • Barclays reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Barclays sold 10,944 SAVIENT PHARMACEUTICALS INC shares in Q4 2013.
  • Barclays first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Barclays's SAVIENT PHARMACEUTICALS INC position peaked at $110K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q4 2013.

Based on Barclays's 13F filing for Q4 2013, filed 13 Feb 2014.